Best Biotechnology Stocks: Alkermes ($ALKS)

My fundamental view on Alkermes is currently available on the Motley Fool.

The stock spent most of 2011 and 2012 contained by $20 resistance as the S&P posted new swing highs, it was only in the latter part of 2012 that Alkermes was able to hold a break of $20. Since meeting the measured move target of $26.50 the stock has followed with a new consolidation phase.

The current advance is tightening into a bearish wedge with key weekly support at $30.  The latter will be an opportunity for a long position in the coming week. However, the daily chart shows potential for a move to $27-28 as part of a gap close from April - potential buyers may be best to wait until then.  Momentum buyers would need a volume break of $35 to get excited as the stock has traded sideways since April's earnings; playing the momentum side offers a measured move upside target of $42.30.  Again, those getting in at $27 or $30 could hold for this on a push above $35. Stops should be considered on a loss of $25.50

Technicals are a bit 'meh'.  On-Balance-Volume is on a 'buy' signal, although the MACD trigger line is on a clear 'sell' trigger and is about to break the zero line; an effective bearish confirmation. Stochastics and ADX (+DI/-DI) are neutral with a slight bearish bias. Bears "win" the technical argument, although this could quickly change given their positioning.


All Contributions Welcome - Thank You!

Follow Me on Twitter

Dr. Declan Fallon is the Senior Market Technician and Community Director for
You can read what others are saying about Zignals on


Popular posts from this blog

Markets attempt a swing low for the seven day decline

Low volume selling after Russell 2000 breakout

Minor losses pressure Thursday's reversal attempt